Loading…
for educational and safety purposes
class, effects, and the receptor fingerprint, side by side; add up to four, then source the whole stack
Popular head-to-heads →AMPA receptorspositive modulator
Acetylcholine releaseincreases
Phospholipid metabolismboosts
Dopamine (prefrontal)facilitates
Broad CNS receptor safety panel (19 targets, including NMDA GRIN1, GABA-A alpha1, muscarinic M1 and M3, nicotinic alpha4, D2, 5-HT2C, adenosine A1 and A3, mu- and kappa-opioid, alpha1A/alpha2B/beta1-adrenergic, H1, DAT, NET, hERG, ENT1)No measurable activity; this is a negative result and the best-supported target fact about the compound
AMPA-type ionotropic glutamate receptorPositive modulation (functional; increases agonist efficacy, not potency)
Cortical and hippocampal cholinergic transmission (acetylcholine utilisation, high-affinity choline uptake)Indirect presynaptic enhancement
NMDA receptor, glycine co-agonist site (functional)Reversal of kynurenic acid antagonism
Protein kinase C (membrane translocation and activation)Transient activator followed by down-regulation
Depolarisation-evoked excitatory amino acid release (hippocampus)Biphasic enhancement, with an inverted-U concentration response
alpha7 nicotinic acetylcholine receptor / PI3K-Akt signallingUpregulation (enantiomer-specific, indirect, protein-expression level)
AMPA receptorspositive modulator
Acetylcholine releaseincreases
mGluR1 / mGluR5modulates
Dopamine D2 / 5-HT2Amild agonist
checking Oxiracetam and Aniracetam: no adverse interactions were flagged (1 compatible pair); the pairs read as compatible at the class level.
noted as a compatible pairing in Oxiracetam's own profile; no adverse interaction flagged.
General educational info, not medical advice.
The vendors that carry the most of your 2 picks; fewer vendors, fewer codes, less shipping.